Researchers demonstrate activity of mebendazole in metastatic melanoma

Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.

Read the whole article on Physorg

More from Physorg